India and the United Arab Emirates (UAE) have long shared a robust economic relationship. This partnership has grown particularly strong in the pharmaceutical sector, where India stands as one of the largest exporters of high-quality yet cost-effective medicines, vaccines, and Active Pharmaceutical Ingredients (APIs). PHARMEXCIL, the Pharmaceutical Export Promotion Council of India, has reaffirmed its commitment to nurturing this collaboration with key initiatives ahead of the prestigious Arab Health 2025.
Strengthening Strategic Ties
On January 23, 2025, PHARMEXCIL’s Director General, Mr. Raja Bhanu, and Honorary Advisor, Mr. AVPS Chakravarthi, met His Excellency Aref Ali Alnuaimi, Consul General of the UAE, in Hyderabad. This significant meeting focused on enhancing bilateral cooperation in pharmaceuticals, with discussions revolving around increasing trade, fostering innovation, and collaborating in critical areas like drug development, formulations, and APIs.
The UAE has emerged as a key market for Indian pharmaceutical exports, and this meeting reinforced the shared vision to deepen economic and commercial ties. As both nations prioritize healthcare and innovation, their collaboration is poised to create new opportunities that benefit the global healthcare ecosystem.
India Pavilion at Arab Health 2025
A key highlight of this growing partnership will be PHARMEXCIL’s representation at Arab Health 2025, one of the world’s most prestigious healthcare and pharmaceutical exhibitions. Scheduled from January 27-30, 2025, at the World Trade Center in Dubai, the event will showcase the best of Indian pharmaceutical innovation and manufacturing capabilities.
The India Pavilion, inaugurated by H.E. Satish Kumar Siven, Consul General of India to the UAE, will feature participation from 65 leading Indian pharmaceutical companies. These companies will present their advanced products, including cutting-edge formulations, APIs, vaccines, and healthcare solutions, to a global audience of healthcare professionals, business leaders, and policymakers.
A Vision for Mutual Growth
PHARMEXCIL’s efforts at Arab Health 2025 aim to position India as a leader in affordable and innovative healthcare solutions. The event provides an unmatched opportunity for Indian pharmaceutical companies to network, explore new markets, and strengthen partnerships within the UAE and the larger Gulf Cooperation Council (GCC) region.
Commenting on this initiative, Mr. Raja Bhanu stated, “India and the UAE share a deep-rooted partnership that has evolved into a strategic collaboration. Arab Health 2025 will be a significant milestone, allowing us to demonstrate India’s capabilities in the pharmaceutical sector while identifying new opportunities to serve the UAE and other global markets.”
Why Arab Health Matters
Arab Health is not just an exhibition but a platform where innovation meets collaboration. With thousands of exhibitors and attendees from over 70 countries, it is the ideal stage for Indian companies to highlight their contributions to the global pharmaceutical supply chain. From discussions on regulatory harmonization to exploring joint ventures, the event is expected to drive impactful outcomes.
Invitation to Stakeholders
PHARMEXCIL extends a warm invitation to healthcare professionals, business leaders, and stakeholders from across the globe to visit the India Pavilion at Arab Health 2025. This is a unique opportunity to experience India’s excellence in pharmaceutical innovation and explore mutually beneficial collaborations.
As India and the UAE continue to align their goals in healthcare, PHARMEXCIL’s efforts will further solidify this partnership, unlocking new potential for both nations and the global healthcare industry.
